[68ga]ga-nota-g5
Liver Cancer
RenJi HospitalradiopharmaceuticalN/AActive
D
28/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 65/ 100
Competitive context
111 Active assets in the Liver Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bxcl501 Uppsala University Hospital | Phase 4 | BBB |
Inno-206 Shanghai Zhongshan Hospital | Phase 4 | BB |
Eloxatin Sun Yat-sen University | Phase 3 | BB |
S-Ketamine The Second Affiliated Hospital of Chongqing Medical University | Phase 4 | BB |
Sorafenib First Affiliated Hospital Xi'an Jiaotong University | Phase 3 | BB |
View all 50 →
Same molecule, other indications
[68ga]ga-nota-g5 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →